+ 2.58
+ 0.78%
+ 2.29
+ 0.66%
+ 2.93
+ 0.7%
+ 1.55
+ 0.91%

Eight Stocks Insiders Are Buying

September 12, 2011 6:46 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company — they believe the stock price will move higher and they want to profit from it. Market-driven sell-offs provide a perfect opportunity for investors who have faith in a company to snap up shares. Here are some stocks that have seen insider buying recently.

American Railcar Industries (NASDAQ: ARII): Director and activist investor Carl Icahn has been periodically buying shares of this company, a subsidiary of Icahn Enterprises, since the beginning of August, including more than 27,000 shares worth more than $11.6 million last week. American Railcar has a market cap of $341.2 million and its dividend yield is 0.8%. The share price is about 21% lower than it was 90 days ago but is more than 27% higher than a year ago. The stock has underperformed the Dow Jones Industrial average since the beginning of the year.

Associated Banc-Corp (NASDAQ: ASBC): More than 150,000 shares, worth over $3.7 million, of this regional bank holdings company were bought last week by the CEO, a vice chairman, and ten others. This Green Bay, Wisc.-based financial services provider has a market cap of $1.7 billion and a dividend yield of 0.4%. Its share price dropped more than 16% in the past month and shares are trading near the 52-week low. But year to date, the stock’s performance has been in line with competitors Northern Trust (NASDAQ: NTRS) and Fifth-Third Bank (NASDAQ: FITB).

Bank of New York Mellon (NYSE: BK): The CEO and the CFO purchased 75,000 shares, worth more than $1.5 million, earlier this month, and a vice chairman bought another $1 million’s worth in August. This New York-based financial giant has a dividend yield of 2.6%, a market cap of $24.6 billion, and a long-range EPS growth forecast of 12.3%. Shares have traded between $19 and $21 since early August, down from a 52-week high of $32.50. The stock has outperformed competitor Barclays (NYSE: BCS) but underperformed JPMorgan Chase (NYSE: JPM) year to date.

Mueller Industries (NYSE: MLI): Last week, two directors bought more than 570,000 shares, worth more than $25 million. This Memphis-based metal fabrication company has a dividend yield of 0.9% and a market cap of $1.7 billion. Its share price has pulled back about 9% from a recent 52-week high but it is still up almost 34% since the beginning of the year. The stock has outperformed competitor Precision Castparts (NYSE: PCP) and the Dow Jones Industrial Average over the past six months.

Prospect Capital (NASDAQ: PSEC): Earlier this month, the CEO and COO bought more than 290,000 shares of this private equity firm, worth more than $2.5 million. In fact the CEO and other insiders have been scooping up shares since May. This New York-based firm focuses on the energy sector in North America and has a market cap of $928.1 million. Its dividend yield is 14.3%. Shares have bounced back from a recent 52-week low but are still almost 20% lower than 90 days ago. The stock has outperformed competitor NGP Capital Resources (NASDAQ: NGPC) year to date.

Overseas Shipholding (NYSE: OSG): Since the beginning of August, six directors and two senior vice presidents have been purchasing shares, including more than 65,000 shares, worth nearly $1.1 million since the beginning of this month. This New York-based ocean transporter of oil and petroleum products has a market cap of $493.5 million and a dividend yield of 5.4%. The share price has been falling since the beginning of the year, including about 9% in the past week. The stock has underperformed the broader markets year to date but outperformed competitor Frontline (NYSE: FRO).

Owens-Illinois (NYSE: OI): The CEO of this maker of glass containers for beverages bought more than 121,000 shares, worth over $2 million, last week and two directors bought shares earlier this summer. This S&P 500 component has a market cap of $2.7 billion and a forward earnings multiple of just 5.8. Its shares are trading near a 52-week low after falling nearly 46% in the past six months. The stock has underperformed competitor Silgan Holdings (NASDAQ: SLGN) and the broader markets year to date.

Seattle Genetics (NASDAQ: SGEN): A pair of directors has purchased more than 1.3 million shares, worth more than $20 million, of this biotech company in the past month. The company is a rumored takeover target and sports a market cap of $2.0 billion. Shares fell from a 52-week high above $21 in late June to a 52-week low below $12 in early August, but have come back to end last week at $17.40. Over the past six months, the stock has outperformed competitors Immunogen (NASDAQ: IMGN) and Pfizer (NYSE: PFE) and the broader markets.

Related Articles

Short Interest in Railroad Stocks on the Rise (CNI, CP, KSU)

Ten Stocks Up More Than 50% in the Past 90 Days

Seven Stocks Insiders Are Buying

Cowen Talks American Railcar Industries Move And The Rail Run